Sorry Nalaxone doesn't count...and how many years has King had a problem with Embeda and Pfizer still hasn't figured out how to fix it? Notice the question mark. So basically what you are saying is there are so few studies out there that compare to what Elite has going on and Pfizer doesn't know what it is doing with a one bead Naltrexone leakage problem. Thanks
ALO-2? Elite is working on multiple products. Here are some questions we have been discussing. Maybe you can answer them
The CEO clearly stated as did the President of the company they planned on entering BE trials and 505B2 trials for abuse resistant ANDAs and NDAs this fiscal year and completing BE trials this fiscal year for abuse resistant products
What do you think the ANDAs are?
What do you think the NDAs are?
What do you think they are trialing with the 505B2 trials?
What do you think the 505B2 products started 2 years ago with Actavis/Mikah are?
And since there will not be an announcement or public statement describing the studies as noted by the company, why would we find them on the government website?
Market Data 
Markets 
AI
